title: Long-term prophylaxis with intermediate-purity factor VIII concentrate (Haemate P) in a patient with type 3 von Willebrand disease and recurrent gastrointestinal bleeding.
abstract: Prophylaxis with von Willebrand factor (VWF)-containing concentrates is considered to be a potential approach for patients with von Willebrand disease (VWD) and severe bleeding tendency. We report the case of a 57-year-old man with type 3 VWD and a history of recurrent melaena. Bleeding frequency and severity had progressively increased and the patient showed chronic anaemia and persistent haemoglobin in the stools. Endoscopic examinations revealed multiple vascular mucosal abnormalities (MVA) of the stomach and large bowel. Photocoagulation of some actively bleeding lesions and octreotide did not significantly affect his clinical conditions: six red cell transfusions and >400 000 IU of intermediate-purity factor VIII (FVIII) concentrate (Haemate P) on-demand were needed during 2002. Prophylaxis with Haemate P 40 IU kg(-1) (102 IU kg(-1) VWF:RCo) thrice weekly was associated with improvement of his mean haemoglobin levels, cessation of clear-cut melaena and red cell transfusions and reduction of total Haemate P requirements (-20% over 2003-04). Prophylaxis with Haemate P is still ongoing without any adverse event over a 30-month period. Clinical course and pharmacokinetic evaluations led to administer Haemate P each 72-96 h. Possible vascular complications were excluded by a careful clinical follow up, as the patient suffered from arterial hypertension and diabetes mellitus; thrombophilic abnormalities were previously excluded and no signs of abnormal coagulation activation or FVIII:C levels >150% were detected thereafter. Long-term prophylaxis with Haemate P has been shown to be safe, effective (also in terms of quality of life) and cost saving in this patient with severe gastrointestinal bleeding due to MVA and VWD.
authors.affiliation: Regional Reference Centre for Coagulation Disorders, Department of Clinical and Experimental Medicine, 'Federico II' University, Naples, Italy. antocopp@unina.it
authors.forename: A
authors.initials: A
authors.lastname: Coppola
authors.forename: E
authors.initials: E
authors.lastname: Cimino
authors.forename: P
authors.initials: P
authors.lastname: Conca
authors.forename: C
authors.initials: C
authors.lastname: De Simone
authors.forename: A
authors.initials: A
authors.lastname: Tufano
authors.forename: G
authors.initials: G
authors.lastname: Tarantino
authors.forename: A M
authors.initials: AM
authors.lastname: Cerbone
authors.forename: G
authors.initials: G
authors.lastname: Minno
mesh_terms: D005169:Factor VIII / Q000032:analysis / Q000627:therapeutic use*; D006471:Gastrointestinal Hemorrhage / Q000150:complications / Q000188:drug therapy* / Q000503:physiopathology; D006801:Humans; D008134:Long-Term Care; D008297:Male; D008875:Middle Aged; D011788:Quality of Life; D012008:Recurrence; D016896:Treatment Outcome; D014842:von Willebrand Diseases / Q000150:complications / Q000188:drug therapy* / Q000503:physiopathology
chemical_list: D005169:Factor VIII